1
|
Dehghanpir SD, Birkenheuer CH, Yang K, Murelli RP, Morrison LA, Le Grice SFJ, Baines JD. Broad anti-herpesviral activity of α-hydroxytropolones. Vet Microbiol 2017; 214:125-131. [PMID: 29408023 DOI: 10.1016/j.vetmic.2017.12.016] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2017] [Revised: 12/20/2017] [Accepted: 12/22/2017] [Indexed: 01/02/2023]
Abstract
Herpesviruses are ubiquitous in animals and cause economic losses concomitant with many diseases. Most of the domestic animal herpesviruses are within the subfamily Alphaherpesvirinae, which includes human herpes simplex virus 1 (HSV-1). Suppression of HSV-1 replication has been reported with α-hydroxytropolones (αHTs), aromatic ring compounds that have broad bioactivity due to potent chelating activity. It is postulated that αHTs inhibit enzymes within the nucleotidyltransferase superfamily (NTS). These enzymes require divalent cations for nucleic acid cleavage activity. Potential targets include the nuclease component of the herpesvirus terminase (pUL15C), a highly conserved NTS-like enzyme that cleaves viral DNA into genomic lengths prior to packaging into capsids. Inhibition of pUL15C activity in biochemical assays by various αHTs previously revealed a spectrum of potencies. Interestingly, the most potent anti-pUL15C αHT inhibited HSV-1 replication to a limited extent in cell culture. The aim of this study was to evaluate three different αHT molecules with varying biochemical anti-pUL15C activity for a capacity to inhibit replication of veterinary herpesviruses (BoHV-1, EHV-1, and FHV-1) and HSV-1. Given the known discordant potencies between anti-pUL15C and HSV-1 replication inhibition, a second objective was to elucidate the mechanism of action of these compounds. The results show that αHTs broadly inhibit herpesviruses, with similar inhibitory effect against HSV-1, BoHV-1, EHV-1, and FHV-1. Based on immunoblotting, Southern blotting, and real-time qPCR, the compounds were found to specifically inhibit viral DNA replication. Thus, αHTs represent a new class of broadly active anti-herpesviral compounds with potential veterinary applications.
Collapse
Affiliation(s)
- Shannon D Dehghanpir
- Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, United States
| | - Claire H Birkenheuer
- Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, United States
| | - Kui Yang
- Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, United States
| | - Ryan P Murelli
- Department of Chemistry, Brooklyn College, The City University of New York, Brooklyn, NY, PhD Program in Chemistry, The Graduate Center, The City University of New York, New York, NY, United States
| | - Lynda A Morrison
- Department of Molecular Microbiology & Immunology, Saint Louis University School of Medicine,St. Louis, MO, United States
| | - Stuart F J Le Grice
- Center for Cancer Research, National Cancer Institute, Frederick, MD, United States
| | - Joel D Baines
- Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, United States.
| |
Collapse
|
2
|
Abstract
Antiviral drug discovery has produced a series of drugs active against herpesviruses in vitro. Several of these are now licensed and/or have been used in clinical practice. This article reviews the mechanisms of action of acyclovir, ganciclovir, penciclovir, sorivudine and foscarnet, the development of resistance to these drugs and their pharmacokinetic and cellular toxicities. Based upon the natural histories of HSV, VZV and CMV, treatment objectives for each virus are discussed and the performance of each drug matched against these objectives. Overall, it is concluded that the perfect drug for treating herpesviruses does not exist, but that significant progress has been made towards controlling several herpesvirus diseases. It is suggested that further progress will require not just improved drug discovery programmes, but also an understanding of different pathogeneses and an appreciation by practising physicians that antiviral drugs must be given early in the infectious process to achieve the best results.
Collapse
Affiliation(s)
- P.D. Griffiths
- Royal Free Hospital School of Medicine, Rowland Hill Street, London NW3 2PF, UK
| |
Collapse
|
3
|
Morfin F, Snoeck R, Andrei G, De Clercq E. Phenotypic Resistance of Herpes Simplex Virus Type 1 Strains Selected in Vitro with Antiviral Compounds and Combinations Thereof. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029600700507] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Several drug-resistant herpes simplex virus type 1 (HSV-1) strains were obtained under the selective pressure of various antiherpetic drugs used alone or in combination. Their susceptibility to a wide range of antiviral compounds was determined. Strains selected under the pressure of brivudin (BVDU) or 1-β-D-arabinofuranosyl-( E)-5-(2-bromovinyl)uracil (BVaraU) alone were composed of two virus populations: (1) virus resistant to BVDU and BVaraU but not to acyclovir (ACV) or ganciclovir (GCV), which is suggestive of an alteration in the thymidylate kinase activity associated with the viral thymidine kinase (TK) (responsible for the phosphorylation of BVDU-monophosphate to BVDU-diphosphate); and (2) virus resistant to BVDU, BVaraU, ACV and GCV, which is indicative of an alteration in the viral TK activity that converts BVDU, BVaraU and other nucleoside analogues such as ACV and GCV to their monophosphate derivatives. Strains resistant to TK-dependent drugs (i.e. ACV, GCV, BVDU and BVaraU) as well as double-mutant strains with decreased sensitivity to both TK-dependent compounds and the pyrophosphate analogues foscarnet (PFA) and phosphonoacetic acid (PAA) (suggestive of mutations at the level of the DNA polymerase) were recovered under the selective pressure of ACV alone or in combination with BVDU or BVaraU. Combinations of BVDU or BVaraU with PFA or PAA led to strains resistant only to BVDU and BVaraU or double-mutant strains resistant to BVDU, BVaraU and the pyrophosphate analogues, but not to strains resistant to other TK-dependent drugs. Interestingly, strains resistant to ACV, BVDU, GCV and/or the pyrophosphate analogues PFA and PAA remained sensitive to the (S)-3-hydroxy-2-phosphonylmethoxypropyl (HPMP) derivatives of cytosine (HPMPC) and adenine (HPMPA).
Collapse
Affiliation(s)
- F. Morfin
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
| | - R. Snoeck
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
| | - G. Andrei
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
| | - E. De Clercq
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
| |
Collapse
|
4
|
Nugier F, Collins P, Larder BA, Langlois M, Aymard M, Darby G. Herpes Simplex Virus Isolates from an Immunocompromised Patient who Failed to Respond to Acyclovir Treatment Express Thymidine Kinase with Altered Substrate Specificity. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029100200504] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Ten sequential post-treatment herpes simplex virus type 1 (HSV-1) isolates were obtained from an immunocompromised patient whose infection, during prolonged treatment, became unresponsive to acyclovir (ACV). Of the ten isolates, eight later isolates were resistant in vitro to ACV and ganciclovir (DHPG), but remained sensitive to 9-β-D-arabinofuranosyladenine (ara-A) and phosphonoformate (PFA). Biochemical characterization of plaque-purified clones of the resistant isolates revealed an altered thymidine kinase (TK) substrate specificity phenotype. The comparative nucleotide sequence analysis of polymerase chain reaction (PCR)-amplified DNA encoding the TK genes of one sensitive and two resistant clones showed a single mutation at nucleotide 527. This change would result in a substitution of arginine by glutamine at residue 176 of the polypeptide, a mutation previously observed in a laboratory isolated variant, SC16 Tr7 (Darby et al., 1986).
Collapse
Affiliation(s)
- F. Nugier
- Laboratoire de Bacteriologie — Virologie, Universite Claude Bernard, Lyon, France
| | - P. Collins
- Department of Molecular Sciences, Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS, UK
| | - B. A. Larder
- Department of Molecular Sciences, Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS, UK
| | - M. Langlois
- Departement d'Etude des Maladies Virales, Laboratoire National de la Sante, 8 avenue Rockefeller, 69373 Lyon Cedex 08, France
| | - M. Aymard
- Laboratoire de Bacteriologie — Virologie, Universite Claude Bernard, Lyon, France
| | - G. Darby
- Department of Molecular Sciences, Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS, UK
| |
Collapse
|
5
|
Ertl P, Snowden W, Lowe D, Miller W, Collins P, Littler E. A Comparative Study of the in vitro and in vivo Antiviral Activities of Acyclovir and Penciclovir. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029500600203] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The antiviral properties of the compounds acyclovir (ACV) and penciclovir (PCV) have been compared in a number of in vitro and in vivo assays. In vitro, both compounds had good activity against herpes simplex virus type 1 (HSV-1) and varicella-zoster virus (VZV), although ACV showed statistically significant superiority. In addition, ACV had greater activity against herpes simplex virus type 2 (HSV-2), human cytomegalovirus (HCMV) and Epstein-Barr virus (EBV). We examined the effect of time of addition and removal of ACV and PCV under a variety of conditions and found similar results with the two compounds under most conditions. However, at a high multiplicity of infection, when all of the cells would be expected to be synchronously expressing large amounts of the viral thymidine kinase, short exposures to PCV appeared to be superior to similar exposures to ACV. In the HSV-1 zosteriform mouse model there was no significant difference between the activities of ACV and PCV, or its prodrug famciclovir (FCV), in once- or twice-daily treatment. The possible significance of these results and those previously reported on the activity of the compounds in humans is discussed.
Collapse
Affiliation(s)
- P. Ertl
- Wellcome Research Laboratories, Beckenham BR3 3BS, UK
| | - W. Snowden
- Wellcome Research Laboratories, Beckenham BR3 3BS, UK
| | - D. Lowe
- Wellcome Research Laboratories, Beckenham BR3 3BS, UK
| | - W. Miller
- Burroughs Wellcome Co., Research Triangle Park, NC 27709, USA
| | - P. Collins
- Wellcome Research Laboratories, Beckenham BR3 3BS, UK
| | - E. Littler
- Wellcome Research Laboratories, Beckenham BR3 3BS, UK
| |
Collapse
|
6
|
Andrei G, Snoeck R, De Clercq E. Differential Susceptibility of Several Drug-Resistant Strains of Herpes Simplex Virus Type 2 to Various Antiviral Compounds. ACTA ACUST UNITED AC 2016. [DOI: 10.1177/095632029700800509] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Drug-resistant herpes simplex virus type 2 (HSV-2) strains were obtained under the selective pressure of acyclovir, ganciclovir, brivudin, foscamet, 2-phosphonyl-methoxyethyl (PME) derivatives of adenine (PMEA) and 2,6-diaminopurine (PMEDAP), and 3-hydroxy-2-phosphonylmethoxypropyl (HPMP) derivatives of adenine (HPMPA) and cytosine (HPMPC; cidofovir). A significant degree of cross-resistance between HPMPC and HPMPA on the one hand, and between PMEA, PMEDAP and foscarnet on the other, was noted, suggesting a different mode of interaction of the PME and HPMP derivatives at the DNA polymerase level. The results described here with HSV-2 agree with the published results for HSV-1 and human cytomegalovirus.
Collapse
Affiliation(s)
- G Andrei
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
| | - R Snoeck
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
| | - E De Clercq
- Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium
| |
Collapse
|
7
|
Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor. Antimicrob Agents Chemother 2012; 56:3587-91. [PMID: 22526302 DOI: 10.1128/aac.00133-12] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
ASP2151 (amenamevir) is a helicase-primase inhibitor against herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. To evaluate the anti-HSV activity of ASP2151, susceptibility testing was performed on viruses isolated from patients participating in a placebo- and valacyclovir-controlled proof-of-concept phase II study for recurrent genital herpes. A total of 156 HSV strains were isolated prior to the dosing of patients, and no preexisting variants with less susceptibility to ASP2151 or acyclovir (ACV) were detected. ASP2151 inhibited HSV-1 and HSV-2 replication with mean 50% effective concentrations (EC(50)s) of 0.043 and 0.069 μM, whereas ACV exhibited mean EC(50)s of 2.1 and 3.2 μM, respectively. Notably, the susceptibilities of HSV isolates to ASP2151 and ACV were not altered after dosing with the antiviral agents. Taken together, these results demonstrate that ASP2151 inhibits the replication of HSV clinical isolates more potently than ACV, and HSV resistant to this novel helicase-primase inhibitor as well as ACV may not easily emerge in short-term treatment for recurrent genital herpes patients.
Collapse
|
8
|
Abstract
More than 25 years after the licensure of aciclovir and then penciclovir, followed by their respective prodrugs valaciclovir and famciclovir, cases of clinically relevant resistance to these drugs in immunocompetent individuals remain very rare. The aim of this review is to focus on the mechanism of action of these anti HSV drugs and then briefly compare this favourable outcome with that of CMV, HIV, HBV and influenza. A central theme is that resistance is an epiphenomenon of failure to suppress virus replication, so that improved potency and selectivity should be prioritised when developing new drugs rather than activity against resistant strains per se.
Collapse
Affiliation(s)
- Paul D Griffiths
- Centre for Virology, UCL Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom.
| |
Collapse
|
9
|
Griffiths PD. Antivirals in the transplant setting. Antiviral Res 2006; 71:192-200. [PMID: 16793148 DOI: 10.1016/j.antiviral.2006.04.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2006] [Revised: 04/27/2006] [Accepted: 04/28/2006] [Indexed: 12/12/2022]
Abstract
Over the past quarter of a century, antiviral drugs have moved from an experimental adventure in transplant patients to a situation where they are used routinely to prevent diseases caused by several viruses. Furthermore, they have significantly reduced several medical complications of transplantation, such as graft rejection, thereby implicating viruses as components of their pathogenesis. By controlling these major complication, the development of these antiviral drugs and their prodrugs, has therefore greatly facilitated the clinical expansion of transplantation, allowing life saving procedures to be offered to more patients who could potentially benefit. This article will briefly summaries which viruses are important following transplantation and outline the evidence-base from randomized controlled clinical trails for the deployment of antiviral drugs to prevent viral diseases.
Collapse
Affiliation(s)
- Paul D Griffiths
- Centre for Virology, Department of Infection, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom.
| |
Collapse
|
10
|
Malvy D, Treilhaud M, Bouée S, Crochard A, Vallée D, El Hasnaoui A, Aymard M. A Retrospective, Case-Control Study of Acyclovir Resistance in Herpes Simplex Virus. Clin Infect Dis 2005; 41:320-6. [PMID: 16007528 DOI: 10.1086/431585] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2004] [Accepted: 03/23/2005] [Indexed: 11/03/2022] Open
Abstract
BACKGROUND Occasional cases of acyclovir resistance have been documented in the treatment of herpes simplex virus (HSV) infection. Thirty-eight subjects with acyclovir-resistant infections were identified in an epidemiological surveillance program involving 1811 HSV-infected subjects in France. METHODS Twenty-three index cases from whom acyclovir-resistant HSV strains had been isolated were compared with 46 control subjects matched for immunological status. Sociodemographic characteristics, features of the acyclovir-resistant HSV episode, history of HSV infection, treatment, outcome, and immunological history were recorded. RESULTS Twenty-two index case patients presented with immunodepression. Sixty-five percent reported clinically manifest recurrences, compared with 33% of matched control subjects. Significantly more index case patients had used antiviral drugs, and they had used them more often than had control subjects. However, 26.1% of index case patients reported no antiviral exposure in the previous 2 years. Two-thirds of the strains recovered from the index case patients were isolated because of suspicion of clinical resistance to acyclovir. CONCLUSIONS Clinical treatment resistance is associated with acyclovir-resistant HSV strains, but acyclovir-resistant strains were also isolated from treatment-naive subjects.
Collapse
|
11
|
Andrei G, Balzarini J, Fiten P, De Clercq E, Opdenakker G, Snoeck R. Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin. J Virol 2005; 79:5863-9. [PMID: 15827202 PMCID: PMC1082774 DOI: 10.1128/jvi.79.9.5863-5869.2005] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2004] [Accepted: 12/02/2004] [Indexed: 11/20/2022] Open
Abstract
A broad variety of herpes simplex virus type 1 clones was selected under a single round of high-dose selection with brivudin. Mutations in the thymidine kinase (TK) genes consisted of 42% frameshift mutations within homopolymer repeats of G's and C's and single nucleotide substitutions (58%) that produced stop codons (Q261 and R281) or a new codon at the site of the substitution (A168T, R51W, G59W, G206R, R220H, Y239S, and T287 M). The A168T change, associated with an altered TK phenotype, proved to be the most commonly selected substitution. For the different mutants, a correlation between phenotype, genotype, and in vivo neurovirulence was observed.
Collapse
Affiliation(s)
- Graciela Andrei
- Katholieke Universiteit Leuven, Rega Institute for Medical Research, Laboratory of Virology, Minderbroedersstraat 10, B-3000 Leuven, Belgium.
| | | | | | | | | | | |
Collapse
|
12
|
Chibo D, Druce J, Sasadeusz J, Birch C. Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus. Antiviral Res 2004; 61:83-91. [PMID: 14670581 DOI: 10.1016/j.antiviral.2003.08.018] [Citation(s) in RCA: 85] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
We characterised the antiviral phenotype and genotype of 41 herpes simplex virus (HSV) strains from patients clinically resistant to acyclovir (ACV). Our results confirm recognised mutational sites as being major determinants of thymidine kinase (tk)-associated ACV resistance, in particular insertions and/or deletions at homopolymer stretches of Gs and Cs (59% of all isolates). Previously described amino acid substitutions in functional sites of the tk were also identified (7% of all isolates). In addition, we identified several stop codons in novel locations on the amino acid sequence (7% of all isolates) and amino acid substitutions (15% of all isolates) likely to be directly responsible for conferring resistance to ACV. When there were no mutations detected in the tk gene (12% of all isolates), mutations in the DNA polymerase gene likely to be important in the generation of resistant virus were identified.
Collapse
Affiliation(s)
- Doris Chibo
- Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, Victoria 3051, North Melbourne, Australia.
| | | | | | | |
Collapse
|
13
|
Stránská R, van Loon AM, Bredius RGM, Polman M, Nienhuis E, Beersma MFC, Lankester AC, Schuurman R. Sequential Switching of Dna Polymerase and Thymidine Kinase-Mediated Hsv-1 Drug Resistance in An Immunocompromised Child. Antivir Ther 2004. [DOI: 10.1177/135965350400900107] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Sequential herpes simplex virus type 1 (HSV-1) isolates were obtained from a paediatric haematopoietic stem cell transplant (HSCT) patient who received prolonged therapy with acyclovir (ACV) followed by foscarnet (PFA) and topical cidofovir (HPMPC) for severe persistent mucocutaneous HSV-1 infection. The isolates were retrospectively studied for drug resistance. The first resistant isolate associated with clinical failure of antiviral therapy emerged 44 days post-ACV treatment initiation. Susceptibility testing revealed an ACV-resistant HSV strain that demonstrated cross resistance to PFA in the absence of any previous PFA treatment. The observed cross resistance was conferred by a single amino acid substitution, Ser724Asn, in the HSV DNA polymerase (DNA pol) gene. During the subsequent course of ACV therapy, the ACV/PFA-cross-resistant isolates were replaced by ACV-resistant, PFA-sensitive isolates. These isolates carried no DNA pol mutations, but had an Arg163His substitution in the thymidine kinase gene. Upon subsequent switching of antiviral therapy from ACV to PFA, the original ACV/PFA-cross-resistant DNA pol mutant re-appeared. Our study shows the emergence of different drug-resistant HSV variants during ongoing, unchanged ACV therapy. Furthermore, a rapid re-selection of the original resistant variant was observed after switch. For optimal antiviral management of HSV infections in HSCT recipients, therapeutic decisions should be guided by drug susceptibility results whenever therapeutic failure is observed and/or when changes in antiviral treatment are considered.
Collapse
Affiliation(s)
- Růžena Stránská
- Department of Virology, Eijkman-Winkler Center, University Medical Center Utrecht, the Netherlands
| | - Anton M van Loon
- Department of Virology, Eijkman-Winkler Center, University Medical Center Utrecht, the Netherlands
| | - Robbert GM Bredius
- Department of Paediatrics, Leiden University Medical Center, the Netherlands
| | - Merjo Polman
- Department of Virology, Eijkman-Winkler Center, University Medical Center Utrecht, the Netherlands
| | - Elske Nienhuis
- Department of Virology, Eijkman-Winkler Center, University Medical Center Utrecht, the Netherlands
| | - Matthias FC Beersma
- Department of Medical Microbiology, Leiden University Medical Center, the Netherlands
| | - Arjan C Lankester
- Department of Paediatrics, Leiden University Medical Center, the Netherlands
| | - Rob Schuurman
- Department of Virology, Eijkman-Winkler Center, University Medical Center Utrecht, the Netherlands
| |
Collapse
|
14
|
Harris W, Collins P, Fenton RJ, Snowden W, Sowa M, Darby G. Phenotypic and genotypic characterization of clinical isolates of herpes simplex virus resistant to aciclovir. J Gen Virol 2003; 84:1393-1401. [PMID: 12771406 DOI: 10.1099/vir.0.18880-0] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
A panel of 10 clinical isolates of herpes simplex virus (HSV) deficient in the expression of thymidine kinase (TK) and phenotypically resistant to aciclovir was characterized. Sequence analysis revealed a variety of mutations in TK (nucleotide substitutions, insertions and deletions), most of which resulted in truncated TK polypeptides. In line with previous reports, the most common mutation was a single G insertion in the 'G-string' motif. One HSV-1 isolate and two HSV-2 isolates appeared to encode full-length polypeptides and, in each case, an amino acid substitution likely to be responsible for the phenotype was identified. Pathogenicity was determined using a zosteriform model of HSV infection in BALB/c mice. The majority of isolates appeared to show impaired growth at the inoculation site compared with wild-type virus. They also showed poor replication in the peripheral nervous system and little evidence of zosteriform spread. One exception was isolate 4, which had a double G insertion in the G-string but, nevertheless, exhibited zosteriform spread. These studies confirmed that TK-deficient viruses display a range of neurovirulence with respect to latency and zosteriform spread. These results are discussed in the light of previous experience with TK-deficient viruses.
Collapse
MESH Headings
- Acyclovir/pharmacology
- Animals
- Antiviral Agents/pharmacology
- Base Sequence
- Cell Line
- Chlorocebus aethiops
- Cricetinae
- DNA, Viral/genetics
- Drug Resistance, Viral
- Female
- Genes, Viral
- Genotype
- Herpesvirus 1, Human/drug effects
- Herpesvirus 1, Human/enzymology
- Herpesvirus 1, Human/genetics
- Herpesvirus 1, Human/isolation & purification
- Herpesvirus 2, Human/drug effects
- Herpesvirus 2, Human/enzymology
- Herpesvirus 2, Human/genetics
- Herpesvirus 2, Human/isolation & purification
- Humans
- Mice
- Mice, Inbred BALB C
- Mutation
- Phenotype
- Simplexvirus/drug effects
- Simplexvirus/enzymology
- Simplexvirus/genetics
- Simplexvirus/isolation & purification
- Thymidine Kinase/genetics
- Vero Cells
- Virulence/genetics
Collapse
Affiliation(s)
- Wendy Harris
- GlaxoSmithKline, UK Virology Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
| | - Peter Collins
- GlaxoSmithKline, UK Virology Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
| | - Rob J Fenton
- GlaxoSmithKline, UK Virology Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
| | - Wendy Snowden
- GlaxoSmithKline, UK Virology Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
| | - Mike Sowa
- GlaxoSmithKline, UK Virology Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
| | - Graham Darby
- GlaxoSmithKline, UK Virology Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
| |
Collapse
|
15
|
Grey F, Sowa M, Collins P, Fenton RJ, Harris W, Snowden W, Efstathiou S, Darby G. Characterization of a neurovirulent aciclovir-resistant variant of herpes simplex virus. J Gen Virol 2003; 84:1403-1410. [PMID: 12771407 DOI: 10.1099/vir.0.18881-0] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
A clinical isolate of herpes simplex virus type 1 that is aciclovir resistant but neurovirulent in mice was described previously. The mutation in this virus is a double G insertion in a run of seven G residues that has been shown previously to be a mutational hotspot. Using a sensitive assay, it has been demonstrated that preparations of this virus are able to induce low but consistent levels of thymidine kinase (TK) activity. However, this activity results from a high frequency mutational event that inserts a further G into the 'G-string' motif and thus restores the TK open reading frame. Passage of this virus through the nervous system of mice results in the rapid selection of the TK-positive variant. Thus, this variant is the major component in virus reactivated from latently infected ganglia. Mutation frequency appears to be influenced by the genetic background of the virus.
Collapse
Affiliation(s)
- Finn Grey
- Division of Virology, Department of Pathology, Cambridge University, Tennis Court Road, Cambridge CB2 1QP, UK
| | - Mike Sowa
- GlaxoSmithKline, UK Virology Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
| | - Peter Collins
- GlaxoSmithKline, UK Virology Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
| | - Rob J Fenton
- GlaxoSmithKline, UK Virology Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
| | - Wendy Harris
- GlaxoSmithKline, UK Virology Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
| | - Wendy Snowden
- GlaxoSmithKline, UK Virology Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
| | - Stacey Efstathiou
- Division of Virology, Department of Pathology, Cambridge University, Tennis Court Road, Cambridge CB2 1QP, UK
| | - Graham Darby
- GlaxoSmithKline, UK Virology Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
| |
Collapse
|
16
|
Gershengorn HB, Darby G, Blower SM. Predicting the emergence of drug-resistant HSV-2: new predictions. BMC Infect Dis 2003; 3:1. [PMID: 12659657 PMCID: PMC154092 DOI: 10.1186/1471-2334-3-1] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2002] [Accepted: 03/24/2003] [Indexed: 11/11/2022] Open
Abstract
BACKGROUND Mathematical models can be used to predict the emergence and transmission of antiviral resistance. Previously it has been predicted that high usage of antivirals (in immunocompetent populations) to treat Herpes Simplex Virus type 2 (HSV-2) would only lead to fairly low levels of antiviral resistance. The HSV-2 predictions were based upon the assumption that drug-resistant strains of HSV-2 would be less infectious than drug-sensitive strains but that the drug-resistant strains would not be impaired in their ability to reactivate. Recent data suggest that some drug-resistant strains of HSV-2 are likely to be impaired in their ability to reactivate. OBJECTIVES (1) To predict the effect of a high usage of antivirals on the prevalence of drug-resistant HSV-2 under the assumption that drug-resistant strains will be less infectious than drug-sensitive strains of HSV-2 and also have an impaired ability to reactivate. (2) To compare predictions with previous published predictions. METHODS We generated theoretical drug-resistant HSV-2 strains that were attenuated (in comparison with drug-sensitive strains) in both infectivity and ability to reactivate. We then used a transmission model to predict the emergence and transmission of drug-resistant HSV-2 in the immunocompetent population assuming a high usage of antivirals. RESULTS Our predictions are an order of magnitude lower than previous predictions; we predict that even after 25 years of high antiviral usage only 5 out of 10,000 immunocompetent individuals will be shedding drug-resistant virus. Furthermore, after 25 years, 52 cases of HSV-2 would have been prevented for each prevalent case of drug-resistant HSV-2. CONCLUSIONS The predicted levels of drug-resistant HSV-2 for the immunocompetent population are so low that it seems unlikely that cases of drug-resistant HSV-2 will be detected.
Collapse
Affiliation(s)
| | - Graham Darby
- Glaxo Wellcome Research and Development, Medicines Research Center, London, UK
| | - Sally M Blower
- UCLA AIDS Institute & Department of Biomathematics, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095-1766, USA
| |
Collapse
|
17
|
Abstract
The quiet pandemic of herpes simplex virus (HSV) infection has plagued humanity since ancient times, causing mucocutaneous infection, such as herpes labialis and herpes genitalis. Disease symptoms often interfere with everyday activities and occasionally HSV infections are the cause of life-threatening or sight-impairing disease, especially in neonates and the immunocompromised patient population. After primary or initial infection the virus persists for life in a latent form in neurons of the host, periodically reactivating and often resulting in significant psychosocial distress for the patient. Currently, no cure is available. In the mid-1950s the first antiviral, idoxuridine, was developed for topical treatment of herpes disease and, in 1978, vidarabine was licensed for systemic use to treat HSV encephalitis. Acyclovir (Zovirax), a potent, specific and tolerable nucleosidic inhibitor of the herpes DNA polymerase, was a milestone in the development of antiviral drugs in the late 1970s. In the mid-1990s, when acyclovir became a generic drug, valacyclovir (Valtrex) and famciclovir (Famvir), prodrugs of the gold standard and penciclovir (Denavir), Vectavir), a close analogue, were launched. Though numerous approaches and strategies were tested and considerable effort was expended in the search of the next generation of an antiherpetic therapy, it proved difficult to outperform acyclovir. Notable in this regard was the award of a Nobel Prize in 1988 for the elucidation of mechanistic principles which resulted in the development of new drugs such as acyclovir. Vaccines, interleukins, interferons, therapeutic proteins, antibodies, immunomodulators and small-molecule drugs with specific or nonspecific modes of action lacked either efficacy or the required safety profile to replace the nucleosidic drugs acyclovir, valacyclovir, penciclovir and famciclovir as the first choice of treatment. Recently though, new inhibitors of the HSV helicase-primase with potent in vitro antiherpes activity, novel mechanisms of action, low resistance rates and superior efficacy against HSV in animal models have been discovered. This review summarises the current therapeutic options, discusses the potential of preclinical or investigational drugs and provides an up-to-date interpretation of the challenge to establish novel treatments for herpes simplex disease.
Collapse
|
18
|
Griffiths PD. Tomorrow's challenges for herpesvirus management: potential applications of valacyclovir. J Infect Dis 2002; 186 Suppl 1:S131-7. [PMID: 12353198 DOI: 10.1086/342960] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Controlled trials suggest that acyclovir/valacyclovir can provide significant clinical benefits when used for prophylaxis in the immunocompromised host. These findings implicate herpesvirus(es) in the pathogenesis of complex medical conditions, including graft rejection and death. However, it is not known which of the 8 herpesviruses are important under particular circumstances. Prime candidates for triggering adverse outcomes are cytomegalovirus (CMV) in solid organ transplant recipients (causing rejection), CMV and human herpesvirus type 6 (HHV-6) in bone marrow transplant patients (causing marrow suppression), and herpes simplex virus, HHV-6, and CMV in AIDS patients (accelerating the rate of human immunodeficiency virus disease progression and death). Other diseases that may have a herpesvirus component or trigger susceptible antiviral agents include atherosclerosis and multiple sclerosis. In the future, clinicians should be alert to novel findings of randomized trials that may provide insight into the pathogenesis of these diseases and the contributions made by clinically silent herpesvirus infections.
Collapse
Affiliation(s)
- Paul D Griffiths
- Department of Virology, Royal Free and University College Medical School, Royal Free Campus, London NW3 2PF, United Kingdom.
| |
Collapse
|
19
|
Danve C, Morfin F, Thouvenot D, Aymard M. A screening dye-uptake assay to evaluate in vitro susceptibility of herpes simplex virus isolates to acyclovir. J Virol Methods 2002; 105:207-17. [PMID: 12270654 DOI: 10.1016/s0166-0934(02)00103-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
The widespread use of acyclovir (ACV) could increase the prevalence of herpes simplex virus (HSV) ACV-resistant isolates, and a screening assay are thus important for routine surveillance of the ACV susceptibility of HSV. A screening dye-uptake assay was developed, based on the conventional dye-uptake assay [J. Biol. Stand. 14 (1986) 201]. The susceptibility of HSV was measured by testing two virus dilutions (10(-1) and 10(-2)) against two ACV concentrations (5 and 10 microM) on Vero cells and expressed as a reduced percentage of viral replication. The reproducibility was evaluated with HSV1 and HSV2 ACV-sensitive and ACV-resistant reference strains introduced as controls in successive series. The dye-uptake by Vero cells, the growth capacity of the HSV strains and the reduction of the viral replication in the presence of acyclovir varied by less than 14, 20 and 30%, respectively. This assay allowed the detection of a heterogenous population containing as few as 20% of ACV-resistant strain. The screening test was applied to 500 HSV isolates in a prospective study, and over 95% of the HSV isolates tested were characterised using a single test. This test appeared to be half the cost and much easier to carry out than the conventional dye-uptake assay, and consequently is well suited for large scale surveillance.
Collapse
Affiliation(s)
- Christelle Danve
- Laboratory of Virology, 8 avenue Rockefeller, 69373 cedex 08, Lyon, France.
| | | | | | | |
Collapse
|
20
|
Kleymann G, Fischer R, Betz UAK, Hendrix M, Bender W, Schneider U, Handke G, Eckenberg P, Hewlett G, Pevzner V, Baumeister J, Weber O, Henninger K, Keldenich J, Jensen A, Kolb J, Bach U, Popp A, Mäben J, Frappa I, Haebich D, Lockhoff O, Rübsamen-Waigmann H. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat Med 2002; 8:392-8. [PMID: 11927946 DOI: 10.1038/nm0402-392] [Citation(s) in RCA: 236] [Impact Index Per Article: 10.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The vast majority of the world population is infected with at least one member of the human herpesvirus family. Herpes simplex virus (HSV) infections are the cause of cold sores and genital herpes as well as life-threatening or sight-impairing disease mainly in immunocompromized patients, pregnant women and newborns. Since the milestone development in the late 1970s of acyclovir (Zovirax), a nucleosidic inhibitor of the herpes DNA polymerase, no new non-nucleosidic anti-herpes drugs have been introduced. Here we report new inhibitors of the HSV helicase-primase with potent in vitro anti-herpes activity, a novel mechanism of action, a low resistance rate and superior efficacy against HSV in animal models. BAY 57-1293 (N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide), a well-tolerated member of this class of compounds, significantly reduces time to healing, prevents rebound of disease after cessation of treatment and, most importantly, reduces frequency and severity of recurrent disease. Thus, this class of drugs has significant potential for the treatment of HSV disease in humans, including those resistant to current medications.
Collapse
|
21
|
Griffiths PD. Resistance in viruses other than HIV. Int J Infect Dis 2002; 6 Suppl 1:S32-7. [PMID: 12044287 DOI: 10.1016/s1201-9712(02)90152-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The aim of this brief paper is to summarize the ways in which viruses develop resistance to currently licensed anti-viral drugs and to comment on their clinical relevance. Specific examples will be chosen to emphasize basic principles of the development of resistance and readers are referred elsewhere to a summary of resistance in HIV that follows the same principles.
Collapse
Affiliation(s)
- Paul D Griffiths
- Royal Free and University College Medical School of UCL, London, UK.
| |
Collapse
|
22
|
Sarisky RT, Bartus HR, Dennis SA, Quail MR, Nguyen TT, Wittrock RJ, Halsey WS, Bacon TH, Leary JJ, Sutton D. Absence of rapid selection for acyclovir or penciclovir resistance following suboptimal oral prodrug therapy of HSV-infected mice. BMC Infect Dis 2001; 1:24. [PMID: 11749671 PMCID: PMC61449 DOI: 10.1186/1471-2334-1-24] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2001] [Accepted: 12/10/2001] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Acyclovir (ACV) resistant herpes simplex virus (HSV) isolates can be readily selected in animal infection models receiving suboptimal ACV treatment, however no comparative studies of the emergence of resistance following suboptimal treatment with valacyclovir (VCV) or famciclovir (FCV), the prodrugs of acyclovir and penciclovir, respectively, have been reported. METHODS Mice (n = 30) were infected with HSV type 1 or 2 in the ear pinnae and administered oral prodrugs at one fifth a dose previously shown to be effective. To select and amplify drug-resistant HSV, a total of seven consecutive in vivo passages with suboptimal treatment were performed for each virus sample and progeny virus from each passage was characterized by the plaque reduction (PRA) and plating efficiency assays (PEA). RESULTS No drug-resistant HSV-2 and only a single drug-resistant HSV-1 variant were identified. Virus recovered from the first three sequential passages of this HSV-1 sample was susceptible by PRA, although the proportion of resistant virus recovered gradually increased upon passage. The resistant HSV-1 phenotype was confirmed by PRA after four sequential passages in mice. Unexpectedly, this in vivo-selected drug-resistant HSV-1 failed to yield an infection completely refractory to treatment in subsequent passages. CONCLUSIONS Sub-optimal therapy of immunocompetent mice with either VCV or FCV did not readily select for HSV-mutants resistant to either ACV or PCV, suggesting that selection of resistance with either prodrug remains difficult using this system. Futhermore, this study suggests that the PEA may represent a useful adjunct to the PRA for monitoring alterations in the proportion of drug-resistant virus even when no change in IC50 is apparent.
Collapse
Affiliation(s)
- Robert T Sarisky
- Department of Host Defense, The Antimicrobial and Host Defense Center of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania, USA
| | - H Ron Bartus
- Department of Host Defense, The Antimicrobial and Host Defense Center of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania, USA
| | - Shelley A Dennis
- Department of Host Defense, The Antimicrobial and Host Defense Center of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania, USA
| | - Matthew R Quail
- Department of Host Defense, The Antimicrobial and Host Defense Center of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania, USA
| | - Tammy T Nguyen
- Department of Host Defense, The Antimicrobial and Host Defense Center of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania, USA
| | - Robert J Wittrock
- Department of Host Defense, The Antimicrobial and Host Defense Center of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania, USA
| | - Wendy S Halsey
- Department of Discovery Genetics, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania, USA
| | | | - Jeffry J Leary
- Department of Host Defense, The Antimicrobial and Host Defense Center of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania, USA
| | - David Sutton
- Department of Host Defense, The Antimicrobial and Host Defense Center of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania, USA
| |
Collapse
|
23
|
Kamiyama T, Kurokawa M, Shiraki K. Characterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir. J Gen Virol 2001; 82:2761-2765. [PMID: 11602787 DOI: 10.1099/0022-1317-82-11-2761] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The nucleotide changes of the DNA polymerase gene and the susceptibility of acyclovir (ACV)-resistant varicella-zoster virus (VZV) mutants to anti-herpetic drugs were determined and compared to those of herpes simplex virus type 1 (HSV-1) mutants. The seven ACV-resistant VZV mutants were classified into three groups, N(779)S, G(805)C and V(855)M, according to the sequences of their DNA polymerase genes. The amino acid substitutions N(779)S and G(805)C were identical in position to the N(815)S and G(814)C mutations in the HSV-1 DNA polymerase mutants, respectively, and the V(855)M amino acid substitution was similar to the HSV-1 V(892)M mutation. All three groups of VZV mutants were susceptible to ACV, phosphonoacetic acid, vidarabine and aphidicolin, at levels similar to those seen with the respective HSV-1 mutants, except for subtle differences that were due possibly to the non-conserved regions in their sequences. Although both the HSV-1 and the VZV DNA polymerase genes show 53% sequence similarity, both viruses essentially show a similar biochemical behaviour.
Collapse
Affiliation(s)
- Tomoko Kamiyama
- Department of Virology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan1
| | - Masahiko Kurokawa
- Department of Virology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan1
| | - Kimiyasu Shiraki
- Department of Virology, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan1
| |
Collapse
|
24
|
|
25
|
Gershengorn HB, Blower SM. Impact of antivirals and emergence of drug resistance: HSV-2 epidemic control. AIDS Patient Care STDS 2000; 14:133-42. [PMID: 10763542 DOI: 10.1089/108729100317911] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Genital herpes, caused by herpes simplex virus type-2 (HSV-2), affects more people world-wide than any other sexually transmitted disease (STD). Antivirals are effective in decreasing the duration of symptoms and in reducing viral shedding; however, currently antiviral usage is extremely low. Increased usage of antivirals would have a beneficial epidemic-level effect (due to the decreased transmission of drug-sensitive strains) as well as potentially a detrimental epidemic-level effect (if drug-resistant strains emerge and are transmitted). Previously, we have developed a mathematical model that we have used to predict (with a degree of uncertainty) the beneficial and the potential detrimental epidemic-level effects of increased antiviral usage. Here, we use our model to make further predictions about the impact of increasing antiviral usage. We calculate the effect, on individual patients, of antiviral usage in terms of: (1) the decrease in the average number of infectious days per year and (2) an individual's lifetime probability of acquiring permanent drug resistance. We also use our model: (1) to determine the probability of eliminating herpes by antivirals and (2) to quantify the effect of increasing antiviral usage on decreasing HSV-2 prevalence. Our results show that theoretically it would be possible to eliminate herpes epidemics by using a drug that does not cure.
Collapse
Affiliation(s)
- H B Gershengorn
- Department of Medicine, University of California San Francisco, USA
| | | |
Collapse
|
26
|
Andrei G, Snoeck R, De Clercq E, Esnouf R, Fiten P, Opdenakker G. Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. J Gen Virol 2000; 81:639-48. [PMID: 10675401 DOI: 10.1099/0022-1317-81-3-639] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Drug-resistant strains of herpes simplex virus type 1 (HSV-1) were selected under the pressure of (S)-3-hydroxy-2-phosphonylmethoxypropyl (HPMP) derivatives of cytosine (HPMPC, cidofovir) and adenine (HPMPA) and 2-phosphonylmethoxyethyl (PME) derivatives of adenine (PMEA, adefovir) and 2,6-diaminopurine (PMEDAP). HPMPC-resistant (HPMPC(r)) and HPMPA(r) strains were cross-resistant to one another, but they remained sensitive to foscarnet (PFA), acyclovir (ACV) and the PME derivatives, while the PMEA(r) and PMEDAP(r) strains showed cross-resistance to PFA and ACV. The PMEA(r), PMEDAP(r) and PFA(r) mutants all revealed a single nucleotide change resulting in a Ser-724 to Asn mutation within the conserved region II of the DNA polymerase. Two HPMPA(r) clones and one HPMPC(r) clone possessed single amino acid changes in the DNA polymerase (HPMPA(r) clone D1, Leu-1007 to Met; HPMPA(r) clone B5, Ile-1028 to Thr; HPMPC(r) clone C3, Val-573 to Met). The HPMPC(r) clone A4 contained two mutations, Ala-136 to Thr and Arg-700 to Met. The mutation at position 136, located outside the catalytic domain of the enzyme, was not detected in other HPMPC(r) clones, suggesting that this mutation may not be responsible for the resistant phenotype. Residue 573 is located within the 3'-->5' exonuclease editing domain close to the catalytically important residues Tyr-577 and Asp-581. Similarly, residue 700 is located in the palm subdomain of the catalytic domain, adjacent to the Asp residues 717, 886 and 888 that are vital for polymerase activity. The HPMPA(r) mutations at residues 1007 and 1028, beyond the last conserved region, still fall within the thumb subdomain of the catalytic domain. The different drug-resistant mutants varied in neurovirulent behaviour, the HPMPC(r) strains showing reduced neurovirulence compared with the wild-type.
Collapse
Affiliation(s)
- G Andrei
- Laboratory of Antiviral Chemotherapy, Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium.
| | | | | | | | | | | |
Collapse
|
27
|
Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. The selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Reproduced from Proc. Natl. Acad. Sci. USA 74, 5716-5720 (1977). Rev Med Virol 1999; 9:147-52; discussion 152-3. [PMID: 10479776 DOI: 10.1002/(sici)1099-1654(199907/09)9:3<147::aid-rmv255>3.0.co;2-p] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
28
|
Griffiths P. Herpes/HIV/hepatitis viruses: biological similarities despite taxonomic differences. Rev Med Virol 1998; 8:117-118. [PMID: 10398499 DOI: 10.1002/(sici)1099-1654(199807/09)8:3<117::aid-rmv223>3.0.co;2-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- P Griffiths
- Dept. Virology, Royal Free Hospital, London NW3 2QG
| |
Collapse
|
29
|
Blower SM, Porco TC, Darby G. Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nat Med 1998; 4:673-8. [PMID: 9623975 DOI: 10.1038/nm0698-673] [Citation(s) in RCA: 90] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Genital herpes, caused by herpes simplex virus, is the most prevalent sexually transmitted disease worldwide. In many developing countries genital herpes is untreated, and in the United States only 10% of cases are treated. We present a mathematical model that we use as a health policy tool to predict the levels of antiviral drug resistance that would emerge, if treatment rates were increased, and to identify the key factors in determining the emergence of drug resistance. We use our results to suggest control measures for herpes epidemics that would prevent the emergence of substantial levels of antiviral drug resistance.
Collapse
Affiliation(s)
- S M Blower
- Department of Medicine, University of California San Francisco, 94143, USA
| | | | | |
Collapse
|
30
|
Christophers J, Clayton J, Craske J, Ward R, Collins P, Trowbridge M, Darby G. Survey of resistance of herpes simplex virus to acyclovir in northwest England. Antimicrob Agents Chemother 1998; 42:868-72. [PMID: 9559798 PMCID: PMC105557 DOI: 10.1128/aac.42.4.868] [Citation(s) in RCA: 155] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Acyclovir (ACV) has been used for more than 15 years in the management of herpes simplex virus (HSV) and varicella-zoster virus (VZV) disease. The present survey was undertaken to assess the level of ACV resistance in the population. More than 2,000 HSV isolates from both immunocompetent and immunocompromised patients in northwest England were collected over a 2-year period and tested for sensitivity to ACV. These studies suggested a prevalence of resistance of approximately 0.1 to 0.6% in immunocompetent individuals, with no apparent difference in prevalence between treated and untreated groups. In line with previous studies, the prevalence of resistance in treated immunocompromised individuals was approximately 6%.
Collapse
Affiliation(s)
- J Christophers
- Manchester Public Health Laboratory, Withington Hospital, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
31
|
Bowen EF, Johnson MA, Griffiths PD, Emery VC. Development of a point mutation assay for the detection of human cytomegalovirus UL97 mutations associated with ganciclovir resistance. J Virol Methods 1997; 68:225-34. [PMID: 9389413 DOI: 10.1016/s0166-0934(97)00131-6] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
A point mutation assay was developed to detect the quantitative prevalence of mutations at codons 460 (M to I; M to V), 520 (H to Q), 594 (A to V) and 595 (L to F; L to S) within the UL97 gene of human cytomegalovirus which segregate with ganciclovir resistance. Synthetic mixtures of wild-type and mutant plasmids containing the UL97 gene were amplified by nested polymerase chain reaction and the 700 base pair amplicon subsequently subjected to the point mutation assay. In plasmid reconstruction experiments, there was a high correlation between experimentally derived percentage mutant with the theoretical values. The assay was then used to assess the changes in the genetic composition of the UL97 gene in three patients on prolonged ganciclovir therapy. All three patients developed genotypic resistance against ganciclovir involving mutation at codon L595S, L595F and double mutation at codons L595F and M460I. In one patient, alteration of therapy to foscarnet did not affect the composition of UL97 and virus remained genotypically resistant to ganciclovir. In contrast, in two patients whose therapy was altered to cidofovir (HPMPC), repopulation with cytomegalovirus strains carrying the wild-type (ganciclovir-sensitive) codon at positions 595 and 460 occurred. The potential use of this assay for the rapid detection of cytomegalovirus resistance in patients on long-term ganciclovir therapy is discussed.
Collapse
Affiliation(s)
- E F Bowen
- Department of Virology, Royal Free Hospital School of Medicine, London, UK
| | | | | | | |
Collapse
|
32
|
Oxford JS, al-Jabri AA, Stein CA, Levantis P. Analysis of resistance mutants of viral polymerases. Methods Enzymol 1996; 275:555-600. [PMID: 9026659 DOI: 10.1016/s0076-6879(96)75031-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- J S Oxford
- Academic Virology and Retroscreen Ltd., The London Hospital Medical College, Whitechapel, England
| | | | | | | |
Collapse
|
33
|
Leahy BJ, Christiansen KJ, Collins P. A blinded comparison of two methods of viral susceptibility testing: plaque reduction assay versus microplate in situ ELISA. J Virol Methods 1996; 56:85-90. [PMID: 8690771 DOI: 10.1016/0166-0934(95)01957-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Viral susceptibility testing has been shown to have a role in the management of patients with herpes simplex infections. In this study, 25 isolates of herpes simplex virus representing a broad spectrum of acyclovir-susceptible and -resistant phenotypes were tested using a microplate in situ enzyme-linked immunosorbent assay (MISE). This method is objective and more rapid than the traditional plaque reduction assay (PRA). The previously derived PRA results were not known at the time of testing with the MISE method. The correlation coefficient between PRA and MISE was 0.85. Agreement on sensitive or resistant was reached for 21 of 25 isolates. The standardised microplate in situ ELISA was found to be an acceptable alternative to the plaque reduction assay.
Collapse
Affiliation(s)
- B J Leahy
- Department of Microbiology, Royal Perth Hospital, Australia
| | | | | |
Collapse
|
34
|
Li YY, Minagawa H, Tanaka S, Mori R. Suppression of infectious virus spread to the liver by foscarnet following lethal infection of acyclovir-resistant herpes simplex virus type 2 in mice. Antiviral Res 1995; 27:111-21. [PMID: 7486949 DOI: 10.1016/0166-3542(94)00087-o] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Patients with the acquired immune deficiency syndrome (AIDS) occasionally develop hepatitis, pneumonia or esophagitis due to herpes simplex virus type 2 (HSV-2) infection. HSV hepatitis is a rare but serious complication in liver transplantation. Acyclovir-resistant HSV strains may emerge in immunocompromised patients. Following intraperitoneal inoculation, HSV-2 induces necrotizing hepatitis in mice. We studied the virus spread and mortality following intraperitoneal inoculation of HSV-2 RK (an acyclovir-resistant recombinant virus with altered thymidine kinase activity) as compared to its parent virus 8620K. Neither the 50% lethal dose (LD50) nor the average survival time was significantly different between the two strains. Parenteral acyclovir treatment was found to be effective against 8620K but not RK infection. Parenteral foscarnet treatment was effective against both RK and 8620K, and also inhibited the spread of either virus to the liver, spinal cord and brain. Peroral foscarnet administration was found to prevent the virus growth in the liver.
Collapse
Affiliation(s)
- Y Y Li
- Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka, Japan
| | | | | | | |
Collapse
|
35
|
Affiliation(s)
- R Snoeck
- Rega Institute for Medical Research, Leuven, Belgium
| | | |
Collapse
|
36
|
Leahy BJ, Christiansen KJ, Shellam G. Standardisation of a microplate in situ ELISA (MISE-test) for the susceptibility testing of herpes simplex virus to acyclovir. J Virol Methods 1994; 48:93-108. [PMID: 7962265 DOI: 10.1016/0166-0934(94)90092-2] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Viral susceptibility testing has been traditionally performed by plaque reduction assay (PRA) which is labour intensive, time consuming and requires subjective input by the reader. An in situ enzyme-linked immunosorbent assay (ELISA) method has been developed with the potential to overcome many of the limitations of PRA, and has been applied to a variety of viruses. Previous reports of ELISA susceptibility assays have shown little standardisation between these methods, or any significant analysis of the variable factors which may influence the outcome of the assay. This study optimised the sensitivity of a microplate in situ ELISA (MISE-test) for the detection of viral growth, manipulated the interaction between cells, virus and acyclovir to determine the effect of their relationship on susceptibility results, and established standard assay conditions based on quality controlled parameters such as assay variability and linear ranges. 33 isolates of HSV-2 were tested for susceptibility to acyclovir by PRA, and the standardised MISE. Factors which were critical to the performance of the MISE included inoculum size, inoculation method, duration of incubation, fixative type, immunoglobulin working strengths and choice of chromogenic substrate. Using the ELISA it was possible to separate sensitive HSV-2 isolates from resistant isolates applying a cutoff ID50 value of 2.0 mg/l. The correlation coefficient between PRA and MISE was 0.65. The standardised microplate in situ ELISA was found to be an acceptable alternative to the plaque reduction assay.
Collapse
Affiliation(s)
- B J Leahy
- Department of Microbiology, Royal Perth Hospital, Australia
| | | | | |
Collapse
|
37
|
Abstract
The introduction of virus-specific anti-herpes virus agents such as acyclovir, ganciclovir and Foscarnet has had a significant impact on the management of herpes virus infections. The use of specifically acting antimicrobial agents, however, raises the question of drug resistance. Exposure in cell culture of herpes virus to these agents results in the selection of drug-resistant variants, with resistance being due to alterations in the genes encoding the target enzymes involved in the mechanism of action of the drugs concerned, e.g. in the case of acyclovir resistance occurs as a result of deletions or alterations in the thymidine kinase (TK) or alterations in DNA polymerase genes. Pathogenicity studies reveal that drug-resistant variants are disadvantaged, in particular the TK deletion variants which are less pathogenic and unable to reactivate from latent infections. Extensive studies in cell culture and animal models with herpes viruses have provided an understanding of the mechanisms of resistance and more recently these findings have been correlated with the clinical experience. The incidence of virus resistance in immunocompetent patients is extremely rare, whereas resistance has infrequently been reported in immunocompromised individuals where exposure to drug is prolonged. However, the understanding of the mechanisms and consequences of virus resistance gained in cell culture and in animal models has led to the successful management of resistant episodes in the clinic, either by temporary removal of the selection pressure or by providing alternative therapies.
Collapse
Affiliation(s)
- P Collins
- Department of Molecular Sciences, Wellcome Research Laboratories, Beckenham, Kent, U.K
| |
Collapse
|
38
|
Tanaka S, Toh Y, Mori R. Molecular analysis of a neurovirulent herpes simplex virus type 2 strain with reduced thymidine kinase activity. Arch Virol 1993; 131:61-73. [PMID: 8392322 DOI: 10.1007/bf01379080] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Thymidine kinase (TK) of herpes simplex virus (HSV) has been identified as one of the factors responsible for its virulence. We have previously isolated acyclovir (ACV)-resistant HSV type 2 (HSV-2), strain YS-4 C-1, by simple plaque cloning from a clinical isolate. Although YS-4 C-1 had extremely low TK activity, it retained high virulence in mice. To determine the mechanism of the reduction of TK activity, a molecular analysis of the YS-4 C-1 TK gene was performed. YS-4 C-1 produced TK mRNA, which was indistinguishable both in size and amount from that of wild-type strains. However, the YS-4 C-1 TK had a single amino acid change from serine to asparagine at amino acid residue 182 of the TK polypeptide, which was caused by a single nucleotide mutation. It was situated within a highly conserved region (162-194) and close to the putative nucleoside-binding site (169-177), one of the three active centers of TK. In order to confirm the effect of this missense mutation on both the TK activity and neurovirulence, the mutation was introduced into the TK genes of wild-type strains. Although all the recombinants were altered to ACV-resistant viruses with reduced TK activity, they retained high neurovirulence for mice. Our study thus suggested that this mutant TK, in spite of low activity, might play a role in the neurovirulence of HSV-2.
Collapse
Affiliation(s)
- S Tanaka
- Department of Virology, School of Medicine, Kyushu University, Fukuoka, Japan
| | | | | |
Collapse
|
39
|
Griffiths PD. Future management of herpesvirus infections. J Med Virol 1993; Suppl 1:165-8. [PMID: 8245886 DOI: 10.1002/jmv.1890410532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
The clinical investigations conducted to date with herpesviruses have provided a good grounding into the general principles of herpesvirus replication and pathogenesis. Multiple opportunities for intervention include prevention of initial infection, prevention of reactivation, suppression of reactivated virus, and treatment of established disease. Studies have shown that each of these approaches can be effective against one or more herpesviruses. What is needed now are studies combining sequential interventions so that patients who fail, for example, prophylaxis with one drug can be entered directly into trials of suppression and then into pre-emptive therapy, each with different antiviral agents. In this way, it is to be hoped that increasing proportions of cohorts of susceptible patients will suffer less from herpesvirus infections. Clearly, the design of such clinical trials needs to be constantly refined as methods of diagnosis and understanding of pathogenic mechanisms improve and as new agents are discovered.
Collapse
Affiliation(s)
- P D Griffiths
- Department of Virology, Royal Free Hospital School of Medicine, London, United Kingdom
| |
Collapse
|
40
|
Abstract
The discovery of acyclovir marked the beginning of an exciting era in antiviral research. Early studies on the novel mode of action explained the selectivity of the compound and the remarkably narrow spectrum of activity against a subset of the herpesviruses. Throughout the past decade many clinical trials have demonstrated the efficacy and safety of this drug. Furthermore, the development of resistance does not appear to be a significant issue in normal individuals. Acyclovir provided the stimulus for further work in the antiherpes area, and this has led to the recent discovery of an oral prodrug (256U87), which delivers higher levels of acyclovir by the oral route, and to the discovery of 882C87, a highly selective inhibitor of varicella zoster virus. The novel mode of action of acyclovir involves an extremely selective phosphorylation step carried out by the herpesvirus thymidine kinase. It has recently been shown with another nucleoside analogue, ganciclovir, active against human cytomegalovirus (HMCV), that activation can be carried out by other unrelated kinases (in this case the UL97 gene product). Studies of this type may lead to the development of further novel inhibitors.
Collapse
Affiliation(s)
- G Darby
- Molecular Sciences Department, Wellcome Research Laboratories, Beckenham, Kent, United Kingdom
| |
Collapse
|
41
|
Tudor-Williams G, Emery VC. Development ofIn Vitro resistance to zidovudine is likely to be clinically significant. Rev Med Virol 1992. [DOI: 10.1002/rmv.1980020302] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
42
|
Dianzani F, Antonelli G, Turriziani O, Dong G, Capobianchi MR, Riva E. In vitro selection of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine. Antiviral Res 1992; 18:39-52. [PMID: 1384427 DOI: 10.1016/0166-3542(92)90004-o] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
3'-Azido-3'-deoxythymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) was obtained by growing HTLV-IIIB in C8166 cell cultures in the presence of inhibitory concentrations of AZT. The AZT-resistant HIV-1 was capable of replicating, as measured by infectious virus yield, and inducing cytopathic effect in the presence of AZT concentrations able to completely suppress the replication of parental HTLV-IIIB. Cloning of the AZT-resistant HIV-1 revealed that a number of different variants of HIV-1 with various degrees of sensitivity to AZT emerged during propagation of HTLV-IIIB in C8166 cells in the presence of the drug. PCR experiments performed on DNA extracted from C8166 cells infected with a resistant strain revealed that viral DNA was produced in the presence of inhibitory concentrations of AZT, while viral DNA in C8166 cells infected with the parental virus was drastically inhibited. Reverse transcriptase isolated from the AZT-resistant HIV-1 variant failed to show resistance to AZT 5'-triphosphate.
Collapse
Affiliation(s)
- F Dianzani
- Institute of Virology, University La Sapienza, Rome, Italy
| | | | | | | | | | | |
Collapse
|
43
|
Darby G, Larder BA. The clinical significance of antiviral drug resistance. RESEARCH IN VIROLOGY 1992; 143:116-20. [PMID: 1594792 DOI: 10.1016/s0923-2516(06)80091-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- G Darby
- Department of Molecular Sciences, Wellcome Research Laboratories, Beckenham, Kent, UK
| | | |
Collapse
|